Teva Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2000
Net Income	-559	-2,446	417	-3,990	-999	-2,399	-16,525	68	1,573	3,055	Upgrade
Depreciation & Amortization	1,153	1,308	1,330	1,557	1,722	1,842	2,112	1,524	1,308	1,508	Upgrade
Share-Based Compensation	121	124	119	129	119	155	133	124	117	95	Upgrade
Other Operating Activities	653	2,604	-1,068	3,520	-94	2,599	16,245	1,913	2,529	469	Upgrade
Operating Cash Flow	1,368	1,590	798	1,216	748	2,446	2,225	3,890	5,542	5,127	Upgrade
Operating Cash Flow Growth	-13.96%	99.25%	-34.38%	62.57%	-69.42%	9.93%	-42.80%	-29.81%	8.09%	58.39%	Upgrade
Capital Expenditures	-526	-548	-562	-578	-525	-651	-874	-901	-772	-929	Upgrade
Acquisitions	68	61	311	67	343	0	43	-36,148	-3,309	-363	Upgrade
Change in Investments	1,431	1,143	1,773	1,362	1,481	1,616	1,082	854	-2,003	-324	Upgrade
Other Investing Activities	-5	-	1	12	56	901	3,195	1,790	519	166	Upgrade
Investing Cash Flow	968	656	1,523	863	1,355	1,866	3,446	-34,405	-5,565	-1,450	Upgrade
Dividends Paid	0	0	0	0	0	0	-901	-1,303	-1,155	-1,156	Upgrade
Share Issuance / Repurchase	0	0	0	0	0	0	0	364	3,240	14	Upgrade
Debt Issued / Paid	-1,701	-1,369	-2,166	-1,880	-1,863	-3,272	-4,477	26,251	-393	-1,224	Upgrade
Other Financing Activities	-212	-118	-6	-5	-63	-79	-372	-95	3,113	-9	Upgrade
Financing Cash Flow	-1,913	-1,487	-2,172	-1,885	-1,926	-3,351	-5,750	25,217	4,805	-2,375	Upgrade
Exchange Rate Effect	-30	-123	-128	8	16	-142	54	-660	-62	-114	Upgrade
Net Cash Flow	393	636	21	202	193	819	-25	-5,958	4,720	1,188	Upgrade
Free Cash Flow	842	1,042	236	638	223	1,795	1,351	2,989	4,770	4,198	Upgrade
Free Cash Flow Growth	-19.19%	341.53%	-63.01%	186.10%	-87.58%	32.86%	-54.80%	-37.34%	13.63%	90.30%	Upgrade
Free Cash Flow Margin	5.31%	6.98%	1.49%	3.83%	1.32%	9.82%	6.18%	13.65%	24.27%	20.71%	Upgrade
Free Cash Flow Per Share	0.75	0.94	0.21	0.58	0.20	1.76	1.33	3.13	5.58	4.92	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).